Kestra Medical beats Q3 revenue estimates; raises FY guidance
Overview
US wearable medical device maker's fiscal Q3 revenue rose 63%, beating analyst expectations
Adjusted EBITDA loss for fiscal Q3 widened and missed analyst estimates
Company raised FY26 revenue guidance to $93 mln
Outlook
Kestra raises FY26 revenue guidance to $93 mln from $91 mln
Result Drivers
MARKET SHARE AND WCD MARKET EXPANSION - Revenue growth was driven by higher market share and expansion of the wearable cardioverter defibrillator market
IN-NETWORK PATIENTS AND REVENUE CYCLE - Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management
GROSS MARGIN IMPROVEMENT - Gross margin expansion was driven by volume leverage, a higher mix of in-network patients and cost improvement programs
Company press release: ID:nGNX4S9wn
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $24.6 mln | $22.86 mln (7 Analysts) |
Q3 EPS |
| -$0.61 |
|
Q3 Adjusted EBITDA | Miss | -$21.2 mln | -$20.74 mln (6 Analysts) |
Q3 Gross Profit |
| $12.9 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Kestra Medical Technologies Ltd is $30.00, about 55.8% above its March 16 closing price of $19.26
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
